Treatment of bacterial prostatitis

Clinical Infectious Diseases

Volumn 50, Issue 12, 2010, Pages 1641-1652

  Lipsky, Benjamin A ^a,c   Byren, Ivor ^d   Hoey, Christopher T ^b  

^a General Internal Medicine Service   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFACLOR; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTETAN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; NITROFURANTOIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PROSTATITIS; BACTERIURIA; BLOOD CELL COUNT; BLOOD CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG TISSUE LEVEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RATE; MALE; MICTURITION DISORDER; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATITIS; REVIEW; SEXUAL DYSFUNCTION; URINALYSIS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; MALE; PROSTATITIS;

EID: 77952976905     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652861     Document Type: Review

References (99)

1. Liang CZ, Li HJ, Wang ZP, et al. Treatment of chronic prostatitis in Chinese men. Asian J Androl 2009; 11: 153-156.
2. Weidner W, Wagenlehner FM, Marconi M, Pilatz A, Pantke KH, Diemer T. Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: andrological implications. Andrologia 2008; 40: 105-112.
3. Nickel JC, Downey J, Johnston B, Clark J. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001; 165: 1539-1544.
4. Doble A. Chronic prostatitis. Br J Urol 1994; 74: 537-541.
5. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-237.
6. Weidner W, Anderson RU. Evaluation of acute and chronic bacterial prostatitis and diagnostic management of chronic prostatitis/chronic pelvic pain syndrome with special reference to infection/inflammation. Int J Antimicrob Agents 2008; 31(Suppl 1): S91-S95.
7. Turner JA, Ciol MA, Von Korff M, Berger R. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol 2003; 169: 580-583.
8. Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006; 15: 299-305.
9. Clemens JQ, Calhoun EA, Litwin MS, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology 2009; 74: 983-987, quiz 987 el-3.
10. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159: 1224-1228.
11. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001; 165: 842-845.
12. Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 2000; 86: 443-448.
13. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998; 51: 578-584.
14. Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact of chronic prostatitis. Arch Intern Med 2004; 164: 1231-1236.
15. Krieger JN. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol 2004; 56: 99-107.
16. McNaughton Collins M, Pontari MA, O'Leary MP, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001; 16: 656-662.
17. Turner JA, Ciol MA, Von Korff M, Berger R. Health concerns of patients with nonbacterial prostatitis/pelvic pain. Arch Intern Med 2005; 165: 1054-1059.
18. Fair WR, Parrish RF. Antibacterial substances in prostatic fluid. Prog Clin Biol Res 1981; 75A: 247-264.
19. Johnson JR, Kuskowski MA, Gajewski A, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 2005; 191: 46-50.
20. Millan-Rodriguez F, Palou J, Bujons-Tur A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol 2006; 24: 45-50.
21. Ozden E, Bostanci Y, Yakupoglu KY, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 2009; 74: 119-123.
22. Nickel JC, Olson ME, Barabas A, Benediktsson H, Dasgupta MK, Costerton JW Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol 1990; 66: 47-54.
23. Nickel JC, Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. Urology 2005; 66: 2-8.
24. Etienne M, Pestel-Caron M, Chavanet P, Caron F. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis 2008; 46: 951-953; author reply 953.
25. Zegarra Montes LZ, Sanchez Mejia AA, Loza Munarriz CA, Gutierrez EC. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol 2008; 34: 30-37, discussion 38-40.
26. Magri V, Wagenlehner FM, Montanari E, et al. Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications. Asian J Androl 2009; 11: 461-477.
27. Budia A, Luis Palmero J, Broseta E, et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol 2006; 40: 326-331.
28. Rizzo M, Marchetti F, Travaglini F, Trinchieri A, Nickel JC. Prevalence, diagnosis and treatment of prostatitis in Italy: a prospective urology outpatient practice study. BJU Int 2003; 92: 955-959.
29. McNaughton Collins M, Fowler FJ Jr, Elliott DB, Albertsen PC, Barry MJ. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Urology 2000; 55: 403-407.
30. Nickel JC, Shoskes D, Wang Y, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006; 176: 119-124.
31. Schaeffer AJ, Knauss JS, Landis JR, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002; 168: 1048-1053.
32. Nickel JC. Clinical evaluation of the patient presenting with prostatitis. Eur Urol 2003; 2: 11-14.
33. Lee JC, Muller CH, Rothman I, et al. Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. J Urol 2003; 169: 584-587; discussion 587-588.
34. Wise GJ, Shteynshlyuger A. Atypical infections of the prostate. Curr Prostate Rep 2008; 6: 86-93.
35. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 2005; 174: 161-164.
36. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005; 66: 721-725. 37.
37. Naber KG. Management of bacterial prostatitis: what's new? BJU Int 2008; 101(Suppl 3): 7-10.
38. Naber KG, Roscher K, Botto H, Schaefer V. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2008; 32: 145-153.
39. Nickel JC, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol 2008; 179: 1391-1395.
40. Szoke I, Torok L, Dosa E, Nagy E, Scultety S. The possible role of anaerobic bacteria in chronic prostatitis. Int J Androl 1998; 21: 163-168.
41. Skerk V, Krhen I, Schonwald S, et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004; 24(Suppl 1): S53-S56.
42. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003; 49: 269-279.
43. Naber KG, Sorgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003; 35: 331-335.
44. Wagenlehner FM, Weidner W, Sorgel F, Naber KG. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005; 26: 1-7.
45. Shigehara K, Miyagi T, Nakashima T, Shimamura M. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother 2008; 14: 40-43.
46. Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 2008; 8: 12.
47. Ha US, Kim ME, Kim CS, et al. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents 2008; 31(Suppl 1): S96-S101.
48. Magri V, Trinchieri A, Pozzi G, et al. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents 2007; 29: 549-556.
49. de la Rosette JJ, Hubregtse MR, Meuleman EJ, Stolk-Engelaar MV, Debruyne FM. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; 41: 301-307.
50. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008; 31(Suppl 1): S112-S116.
51. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol 2002; 42: 163-166.
52. Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis: management strategies. Drugs 2009; 69: 71-84.
53. El-Hakim A, Shah DK, Smith AD. Advanced therapy for prostatitis: minimally invasive and invasive therapies. Curr Urol Rep 2003; 1: 44-50.
54. Nickel JC, Downey J, Ardern D, Clark J, Nickel K. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004; 172: 551-554.
55. Juricic C, F. KK, Sietzen W, et al. Concentration of amoxicillin and clavulanate in the prostate tissue and in serum: a pharmacokinetic study. Proceedings of the 15th International Congress of Chemotherapy. 1987.
56. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990; 2: 171-177.
57. Klotz T, Braun M, Bin Saleh A, Orlovski M, Engelmann U. Penetration of a single infusion of ampicillin and sulbactam into prostatic tissue during transurethral prostatectomy. Int Urol Nephrol 1999; 31: 203-209.
58. Goto T, Makinose S, Ohi Y, et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 1998; 5: 243-246.
59. Symes JM, Jarvis JD, Tresidder GC. An appraisal of cephalexin monohydrate levels in semen and prostatic tissue. Chemotherapy 1974; 20: 257-262.
60. Litvak AS, Franks CD, Vaught SK, McRoberts JW. Cefazolin and cephalexin levels in prostatic tissue and sera. Urology 1976; 7: 497-499.
61. Smith RP, Schmid GP, Baltch AL, Sutphen NT, Hammer MC. Concentration of cefaclor in human prostatic tissue. Am J Med Sci 1981; 281: 19-24.
62. Vree TB, Hekster YA. Pharmacokinetics and tissue concentrations of cefuroxime. Pharm Weekbl Sci 1990; 12: 262-266; discussion 267.
63. Becopoulos T, Georgoulias D, Constantinides C, Stathakis H, Kosmidis J. Acute prostatitis: which antibiotic to use first. J Chemother 1990; 2: 244-246.
64. Adam D, Schalkhauser K, Boettger F. Diffusion of cefuroxime into the prostatic and other tissues of the urogenital region [in German]. Med Klin 1979; 74: 1867-1870.
65. Fraschini F, Scaglione F, Mezzetti M, et al. Pharmacokinetic profile of cefotetan in different clinical conditions. Drugs Under Experimental and Clinical Research 1988; 14: 547-553.
66. Takeuchi N, Kinukawa T, Matsuura O, et al. A study of prostatic tissue levels of latamoxef, cefoperazone and cefotaxime [in Japanese]. Hinyokika Kiyo 1986; 32: 1831-1841.
67. Fujita K, Fujita HM, Fujii K, et al. Cefotaxime concentration in the prostatic tissue [in Japanese]. Jpn J Antibiot 1983; 36: 1465-1468.
68. Novick WJ Jr. Levels of cefotaxime in body fluids and tissues: a review. Rev Infect Dis 1982; 4(Suppl): S346-S353.
69. Martin C, Viviand X, Cottin A, et al. Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy. Antimicrob Agents Chemother 1996; 40: 1311-1313.
70. Morita M, Hatakeyama T, Suzuki K. Ceftazidime concentration in human prostatic tissue and serum following intravenous injection]. Hinyokika Kiyo 1991; 37: 659-662
71. Morita M, Nakagawa H and Suzuki K. Cefixime concentration in human prostatic tissue following 3-days of administration [in Japanese]. Hinyokika Kiyo 1991; 37: 1581-1584.
72. Naber KG, Kinzig M, Adam D, Sorgel F, Bajorski AH, Kiehn R. Concentrations of Cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 1991; 19: 30-35.
73. Madsen PO, Dhruv R, Friedhoff LT. Aztreonam concentrations in human prostatic tissue. Antimicrob Agents Chemother 1984; 26: 20-21.
74. Whitby M, Hempenstall J, Gilpin C, Weir L, Nimmo G. Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue. Chemotherapy 1989; 35: 7-11.
75. Cannon GM Jr, Smaldone MC, Paterson DL. Extended-spectrum betalactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis. Can J Urol 2007; 14: 3653-3655.
76. Baker SD, Horger DC, Keane TE. Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology 2004; 64: 808-810.
77. Pierce JR Jr, Saeed Q, Davis WR. Prostatic abscess due to communityacquired methicillin-resistant Staphylococcus aureus. Am J Med Sci 2008; 335: 154-156.
78. Bergmann M, Lederer B, Takacs F. Tissue concentrations of sulfametroltrimethoprim in the human prostate [in German]. Urologe A 1979; 18: 335-337.
79. Dan M, Golomb J, Gorea A, Braf Z, Berger SA. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 1986; 30: 88-89.
80. Naber CK, Steghafner M, Kinzig-Schippers M, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001; 45: 293-297.
81. Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-2051.
82. Wagenlehner FM, Kees F, Weidner W, Wagenlehner C, Naber KG. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents 2008; 31: 21-26.
83. Wagenlehner FM, Lunz JC, Kees F, Wieland W, Naber KG. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J Chemother 2006; 18: 485-489.
84. Naber KG, Adam D, Kees F. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs 1987; 34(Suppl l): 44-50.
85. Giberti C, Gallo F, Rosignoli MT, et al. Penetration of orally administered prulifloxacin into human prostate tissue. Clin Drug Investig 2009; 29: 27-34.
86. Foulds G, Madsen P, Cox C, Shepard R, Johnson R. Concentration of azithromycin in human prostatic tissue. Eur J Clin Microbiol Infect Dis 1991; 10: 868-871.
87. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panou C, Adamakis I, Giamarellou H. Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis. J Urol 2001; 165: 97-99.
88. Grabe M, Bishop MC, Bjerklund-Johansen L, et al. Management of urinary and male genital tract infections. European Association of Urology, 2008: 84-88.
89. Cai T, Mazzoli S, Bechi A, et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents 2009; 33: 549-553.
90. Jeong CW, Lim DJ, Son H, Lee SE, Jeong H. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int 2008; 80: 157-161.
91. Giannarini G, Mogorovich A, Valent F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 2007; 19: 304-308.
92. Magri V, Trinchieri A, Ceriani I, Marras E, Perletti G. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. Arch Ital Urol Androl 2007; 79: 93-98.
93. Chen WM, Yang CR, Ou YC, et al. Combination regimen in the treatment of chronic prostatitis. Arch Androl 2006; 52: 117-121.
94. Ziaee AM, Akhavizadegan H, Karbakhsh M. Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. Int Braz J Urol 2006; 32: 181-186.
95. Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004; 141: 581-589.
96. Nickel JC, Downey J, Clark J, et al. Levofloxacin for chronic prostatitis/ chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003; 62: 614-617.
97. Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized doubleblind multicenter study. Urology 2003; 62: 537-541.
98. Naber KG. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2002; 20: 18-27.
99. Hu WL, Zhong SZ, He HX. Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection. Asian J Androl 2002; 4: 163-167.